Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ)
December 19 2016 - 9:13AM
Today on 19 December 2016 at
Enzymatica's extraordinary general meeting in Lund, the meeting
resolved on the number of members of the board of directors,
election of new members of the board of directors and remuneration
to new board members.
Election of new members of the
board of directors
The meeting resolved in accordance with the shareholder proposal
that the board of directors, for the period until the next annual
general meeting, shall consist of six ordinary board members
without deputy board members. The meeting resolved that the current
ordinary board members Lennart Nilsson, Hans Pihl, Nils Siegbahn
and Monica Wallter are dismissed and that Bengt Baron, Mats K
Andersson and Louise Nicolin are elected as new ordinary board
members along with existing ordinary board members. Bengt Baron was
elected chairman of the board. Consequently, the members of the
board of directors do hereafter consist of Bengt Baron (chairman),
Marianne Dicander Alexandersson, Mats K Andersson, Louise Nicolin,
Guðmundur Pálmason and Sigurgeir Guðlaugsson.
Remuneration to new board
members
Remuneration to newly elected ordinary board members was resolved
to be paid in the same amounts (pro rata) as resolved for the
chairman of the board of directors and the ordinary board members
by the annual general meeting 2016, i.e. SEK 180,000 for the
chairman and SEK 120,000 to every other member of the board of
directors (on annual basis).
For more information, please
contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
This information is information
that Enzymatica AB (publ) is obliged to make public pursuant to the
EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out
above, at 0920 CET on August 30, 2016.
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on seven markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit
www.enzymatica.com.
Enzymaticas Certified Adviser is Erik Penser
Bankaktiebolag.
Enzymatica Bullentin from EGM
December 19, 2016
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024